IMNM · XBRL financial data

Immunome financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (IMNM's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	3,565	3,826*	1,029	2,364	2,910	2,738*	2,926	4,015	0	0*	0	0
Research and development	3,823	9,637*	15,369	29,083	37,200	47,890*	36,872	40,451	49,193	50,770*	46,381	59,885
General and administrative	4,375	8,040*	6,005	6,978	9,526	10,446*	10,690	10,042	10,945	12,091*	12,950	18,250
Total operating expenses	8,198	98,479*	133,328	42,373	53,432	85,708*	47,562	50,493	60,138	72,861*	59,331	78,135
Operating income (loss)	(4,633)	(94,653)*	(132,299)	(40,009)	(50,522)	(82,970)*	(44,636)	(46,478)	(60,138)	(72,861)*	(59,331)	(78,135)
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(4,345)	(92,634)*	(129,492)	(36,122)	(47,100)	(80,249)*	(41,640)	(43,397)	(57,457)	(69,900)*	(53,839)	(73,127)
Earnings per share, basic USD per share	(0.36)	—	(2.51)	(0.60)	(0.78)	(1.28)*	(0.52)	(0.50)	(0.65)	(0.74)*	(0.48)	(0.65)
Earnings per share, diluted USD per share	(0.36)	—	(2.51)	(0.60)	(0.78)	(1.28)*	(0.52)	(0.50)	(0.65)	(0.74)*	(0.48)	(0.65)
Weighted average shares, basic thousands of shares	12,202	—	51,544	59,937	60,205	62,808*	79,410	87,011	87,958	94,849*	113,137	113,273
Weighted average shares, diluted thousands of shares	12,202	—	51,544	59,937	60,205	62,808*	79,410	87,011	87,958	94,849*	113,137	113,273

Balance sheet

CSV

Fiscal quarters (IMNM's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	90,641	98,679	269,723	165,332	155,568	143,351	257,613	143,876	272,639	653,482	582,693	217,706
Marketable securities	—	39,463	39,983	113,021	84,562	73,952	59,710	124,160	0	0	—	302,290
Prepaid and other current assets	773	6,561	3,620	5,931	3,910	4,036	5,807	9,396	7,285	7,295	11,616	18,453
Total current assets	91,414	144,703	313,326	284,284	244,040	221,339	323,130	277,432	279,924	660,777	594,309	538,449
Property and equipment, net	1,172	2,073	4,302	6,096	7,172	10,113	10,953	11,025	11,563	14,636	17,081	17,359
Right-of-use asset	345	1,564	1,458	2,523	2,388	4,278	4,163	3,269	3,125	2,978	2,828	3,942
Total assets	93,161	148,540	319,754	296,215	256,898	240,241	342,693	296,290	299,377	683,188	619,792	565,384
Accounts payable	2,786	3,311	7,179	7,047	3,518	14,189	9,126	4,660	6,147	3,339	5,534	5,996
Total current liabilities	23,111	21,829	30,768	39,900	39,528	54,307	30,797	22,878	31,445	44,990	27,412	35,713
Lease liability, non-current	—	1,340	1,206	2,477	2,464	4,769	4,770	4,142	4,013	3,855	3,694	4,588
Total liabilities	87,085	28,658	34,182	42,377	41,992	59,076	35,567	27,020	35,458	48,845	31,106	40,301
Accumulated deficit	(130,173)	(222,807)	(352,299)	(388,421)	(435,521)	(515,770)	(557,410)	(600,807)	(658,264)	(728,164)	(782,003)	(855,130)
Total stockholders' equity	6,076	119,882	285,572	253,838	214,906	181,165	307,126	269,270	263,919	634,343	588,686	525,083
Total liabilities and equity	93,161	148,540	319,754	296,215	256,898	240,241	342,693	296,290	299,377	683,188	619,792	565,384
Common shares outstanding (cover page) thousands of shares	42,730	59,694	59,969	60,054	62,417	86,951	87,012	87,045	91,710	113,133	113,250	113,578

Cash flows

CSV

Fiscal quarters (IMNM's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(4,345)	(92,634)*	(129,492)	(36,122)	(47,100)	(80,249)*	(41,640)	(43,397)	(57,457)	(69,900)*	(53,839)	(73,127)
Stock-based compensation	1,083*	2,883*	2,159	3,227*	4,892*	5,470*	5,703	5,347*	6,747*	7,893*	7,953	8,799*
Depreciation and amortization	111*	151*	157	549*	411*	450*	611	637*	589*	629*	603	957*
Net cash from operating activities	(8,614)*	(17,459)*	(11,170)	(23,397)*	(34,167)*	(42,060)*	(53,055)	(49,401)*	(40,510)*	(47,953)*	(58,638)	(61,692)*
Purchases of property and equipment	36*	349*	2,164	2,344*	1,539*	1,126*	3,665	905*	1,116*	3,999*	3,002	2,176*
Net cash from investing activities	(36)*	(30,002)*	(37,231)	(81,688)*	24,098*	9,758*	5,089	(64,171)*	123,884*	(3,999)*	(12,016)	(304,353)*
Proceeds from issuing common stock	0*	0*	—	—	—	20,000*	—	—	—	0*	—	—
Net cash from financing activities	60,875*	55,499*	219,445	694*	305*	20,085*	162,228	(55)*	45,389*	432,795*	(135)	1,058*
Net change in cash	52,225*	8,038*	171,044	(104,391)*	(9,764)*	(12,217)*	114,262	(113,627)*	128,763*	380,843*	(70,789)	(364,987)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Immunome	217,706	0	(61,692)*	113.6M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Anavex Life Sciences	118,326	not reported	(9,096)*	92.7M	13.0 quarters	Q3 FY26 10-QJun 30, 2026
Pacira BioSciences	205,875	192,399	57,460*	39.9M	—	Q2 FY26 10-QJun 30, 2026
Phibro Animal Health	61,419	396,747*	24,094*	not reported	—	Q4 FY26 10-KJun 30, 2026
uniQure	98,442	5,196	(47,827)*	70.1M	2.6 quarters	Q3 FY26 10-QSep 30, 2026
ImmunityBio	75,670	51,240	(66,494)*	1.1B	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Cogent Biosciences	181,172	not reported	(77,271)*	173.5M	10.3 quarters	Q2 FY26 10-QJun 30, 2026
Syndax Pharmaceuticals	135,941	83,298	(27,254)*	not reported	11.9 quarters	Q3 FY26 10-QSep 30, 2026
Nurix Therapeutics	720,242	673,064	615,631*	109.2M	—	Q3 FY26 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.